
## Mark Waltham

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11913432/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Integrin alpha-2 and beta-1 expression increases through multiple generations of the EDW01 patient-derived xenograft model of breast cancer—insight into their role in epithelial mesenchymal transition in vivo gained from an in vitro model system. Breast Cancer Research, 2020, 22, 136.	2.2	16
2	Identifying Therapies to Combat Epithelial Mesenchymal Plasticity-Associated Chemoresistance to Conventional Breast Cancer Therapies Using An shRNA Library Screen. Cancers, 2020, 12, 1123.	1.7	7
3	Interrogation of Phenotypic Plasticity between Epithelial and Mesenchymal States in Breast Cancer. Journal of Clinical Medicine, 2019, 8, 893.	1.0	45
4	Human-specific RNA analysis shows uncoupled epithelial-mesenchymal plasticity in circulating and disseminated tumour cells from human breast cancer xenografts. Clinical and Experimental Metastasis, 2019, 36, 393-409.	1.7	13
5	Mammographically dense human breast tissue stimulates MCF10DCIS.com progression to invasive lesions and metastasis. Breast Cancer Research, 2016, 18, 106.	2.2	13
6	Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines. Cell Communication and Signaling, 2015, 13, 26.	2.7	47
7	Breast cancer stem cells and epithelial mesenchymal plasticity – Implications for chemoresistance. Cancer Letters, 2013, 341, 56-62.	3.2	108
8	Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor. Cancer Medicine, 2013, 2, 595-610.	1.3	13
9	Structure of the N-terminal domain of human thioredoxin-interacting protein. Acta Crystallographica Section D: Biological Crystallography, 2013, 69, 333-344.	2.5	25
10	An MMP13-Selective Inhibitor Delays Primary Tumor Growth and the Onset of Tumor-Associated Osteolytic Lesions in Experimental Models of Breast Cancer. PLoS ONE, 2012, 7, e29615.	1.1	44
11	Crystallization and preliminary X-ray analysis of the N-terminal domain of human thioredoxin-interacting protein. Acta Crystallographica Section F: Structural Biology Communications, 2011, 67, 613-617.	0.7	8
12	Epithelial-to-Mesenchymal Transitions and Circulating Tumor Cells. Journal of Mammary Gland Biology and Neoplasia, 2010, 15, 261-273.	1.0	201
13	Epithelial Mesenchymal Transition Traits in Human Breast Cancer Cell Lines Parallel the CD44hi/CD24lo/- Stem Cell Phenotype in Human Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2010, 15, 235-252.	1.0	252
14	High Glucose-Induced Thioredoxin-Interacting Protein in Renal Proximal Tubule Cells Is Independent of Transforming Growth Factor-β1. American Journal of Pathology, 2007, 171, 744-754.	1.9	71
15	Vimentin and Epithelial-Mesenchymal Transition in Human Breast Cancer – Observations in vitro and in vivo. Cells Tissues Organs, 2007, 185, 191-203.	1.3	329
16	Upregulation of matrix metalloproteinases (MMPs) in breast cancer xenografts: A major induction of stromal MMP-13. International Journal of Cancer, 2005, 114, 544-554.	2.3	62
17	Antisense-Mediated Suppression of Hyaluronan Synthase 2 Inhibits the Tumorigenesis and Progression of Breast Cancer. Cancer Research, 2005, 65, 6139-6150.	0.4	124
18	Transfection of MDA-MB-231 human breast carcinoma cells with bone sialoprotein (BSP) stimulates migration and invasion inÂvitro and growth of primary and secondary tumors in nude mice. Clinical and Experimental Metastasis, 2004, 21, 19-29.	1.7	41

Mark Waltham

#	Article	IF	CITATIONS
19	Common origins of MDA-MB-435 cells from various sources with those shown to have melonoma properties. Clinical and Experimental Metastasis, 2004, 21, 543-552.	1.7	76
20	LCC15-MB Cells are MDA-MB-435: A Review of Misidentified Breast and prostate cell lines. Clinical and Experimental Metastasis, 2004, 21, 535-541.	1.7	16
21	Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14229-14234.	3.3	463
22	Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Research, 2003, 63, 5243-50.	0.4	144
23	Correlation between extent of osteolytic damage and metastatic burden of human breast cancer metastasis in nude mice: real-time PCR quantitation. Clinical and Experimental Metastasis, 2002, 19, 377-383.	1.7	16
24	Identification of gel-separated tumor marker proteins by mass spectrometry. Electrophoresis, 2000, 21, 679-686.	1.3	92
25	Systematic variation in gene expression patterns in human cancer cell lines. Nature Genetics, 2000, 24, 227-235.	9.4	1,946
26	A gene expression database for the molecular pharmacology of cancer. Nature Genetics, 2000, 24, 236-244.	9.4	1,357
27	Mining and Visualizing Large Anticancer Drug Discovery Databasesâ€. Journal of Chemical Information and Computer Sciences, 2000, 40, 367-379.	2.8	95
28	Rapid mass spectrometric identification of proteins from two-dimensional polyacrylamide gels after in gel proteolytic digestion. Electrophoresis, 1997, 18, 391-402.	1.3	86
29	A protein expression database for the molecular pharmacology of cancer. Electrophoresis, 1997, 18, 647-653.	1.3	87
30	Intrinsic and Acquired Resistance to Methotrexate in Acute Leukemia. New England Journal of Medicine, 1996, 335, 1041-1048.	13.9	225
31	Increased Activity of γ-Glutamyl Hydrolase in Human Sarcoma Cell Lines: A Novel Mechanism of Intrinsic Resistance to Methotrexate (MTX). Advances in Experimental Medicine and Biology, 1993, 338, 635-638.	0.8	36